EVOK Stock Overview
Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Evoke Pharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.44 |
| 52 Week High | US$2.40 |
| 52 Week Low | US$0.42 |
| Beta | 0.30 |
| 1 Month Change | -27.90% |
| 3 Month Change | -33.44% |
| 1 Year Change | -76.99% |
| 3 Year Change | -97.86% |
| 5 Year Change | -94.92% |
| Change since IPO | -99.69% |
Recent News & Updates
Recent updates
Evoke Pharma (NASDAQ:EVOK) Is Using Debt Safely
Jan 22
Evoke to get US patent for nasal spray Gimoti
Sep 20Evoke Pharma Q2 GAAP loss per share narrows, revenue up
Aug 10Evoke Pharma gets Canadian patent linked to Gimoti nasal spray
Jul 06Does Evoke Pharma (NASDAQ:EVOK) Have A Healthy Balance Sheet?
Oct 22Does Evoke Pharma (NASDAQ:EVOK) Have A Healthy Balance Sheet?
Jul 06Evoke Pharma announces positive findings from second GIMOTI market research study
Jun 15Evoke Pharma pops 8% after Gimoti listed in FDA Orange Book
Jun 08Evoke Pharma issued new U.S. patent covering methods of use for Gimoti
Jun 02Evoke Pharma, Inc.'s (NASDAQ:EVOK) Shift From Loss To Profit
Mar 14Evoke Pharma shares surge on positive findings from Gimoti market research study
Jan 13Evoke Pharma EPS beats by $0.02
Nov 10Shareholder Returns
| EVOK | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -8.9% | -0.6% | 1.0% |
| 1Y | -77.0% | 10.6% | 21.9% |
Price Volatility
| EVOK volatility | |
|---|---|
| EVOK Average Weekly Movement | 11.9% |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Volatility Over Time: EVOK's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 4 | Matt D'Onofrio | www.evokepharma.com |
Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers.
Evoke Pharma, Inc. Fundamentals Summary
| EVOK fundamental statistics | |
|---|---|
| Market cap | US$3.70m |
| Earnings (TTM) | -US$7.79m |
| Revenue (TTM) | US$5.18m |
0.7x
P/S Ratio-0.5x
P/E RatioIs EVOK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EVOK income statement (TTM) | |
|---|---|
| Revenue | US$5.18m |
| Cost of Revenue | US$201.88k |
| Gross Profit | US$4.98m |
| Other Expenses | US$12.77m |
| Earnings | -US$7.79m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.92 |
| Gross Margin | 96.10% |
| Net Profit Margin | -150.41% |
| Debt/Equity Ratio | -193.8% |
How did EVOK perform over the long term?
See historical performance and comparison